Skip To Main Content
Yesmino T. Elia on Muck Rack

Yesmino T. Elia

As seen in: Nature, Science Magazine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yesmino T.

Contact Yesmino T., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

SGLT2 inhibition modulates metabolic, vascular, and inflammatory molecular markers in the kidney in youth with type 1 diabetes

|
By Emily Hendrix, Heather Lin Verified, Aditya Barve, Petter Bjornstad, Ye Ji Choi, Phoom Narongkiatikhun, Anil Karihaloo, Pottumarthi Prasad, Kalie L. Tommerdahl, Carissa Birznieks, Antoine Clarke, Yesmino T. Elia, Jacqueline Curtis, Matteo D’Antonio, Hailey E. Hampson, Long Yuan, Jenny E. Kanter, Karin E. Bornfeldt, Tomas Vaisar, Lu-Ping Li, Maninderpal Sethi, Shivani Ramesh, Cheril Clarson, Dylan Weissenkampen, Sarah A. van Eeghen
| Science Magazine Verified
Editor’s summary Abstract Supplementary Materials REFERENCES AND NOTES Information & Authors Metrics & Citations Check Access References Figures Tables Media Share Editor’s summary Sodium-glucose cotransporter-2 (SGLT2) inhibitors can slow diabetic kidney disease, but less is known about their mechanistic benefits in type 1 diabetes. Bjornstad et al.
Open in Who Shared Issue with article?

Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial - Nature Medicine

|
By Farid H. Mahmud, Samantha Anthony, Luc Mertens, Yesmino T. Elia, Pottumarthi Prasad
| Nature Verified
Abstract Sodium glucose co-transporter 2 inhibitors (SGLT2i) reduce the risk of chronic kidney disease (CKD) progression in type 2 diabetes, but their effects in type 1 diabetes (T1D) are not completely understood. ATTEMPT (Adolescent Type 1 Diabetes Treatment with SGLT2i for Hyperglycemia and Hyperfiltration Trial) is a 22-week, double-blind, randomized, placebo-controlled trial to assess dapagliflozin, as an adjunct to insulin, in youth with T1D.
Open in Who Shared Issue with article?
See all 2 articles